21. Goardon, N., et al., Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid
leukemia. Cancer Cell, 2011. 19(1): p. 138-52.
22. Karamitros, D., et al., Single-cell analysis reveals the continuum of human lympho-myeloid
progenitor cells. Nat Immunol, 2018. 19(1): p. 85-97.
23. Alhaj Hussen, K., et al., Molecular and Functional Characterization of Lymphoid Progenitor
Subsets Reveals a Bipartite Architecture of Human Lymphopoiesis. Immunity, 2017. 47(4): p. 680-
696 e8.
24. Kohn, L.A., et al., Lymphoid priming in human bone marrow begins before expression of CD10
with upregulation of L-selectin. Nat Immunol, 2012. 13(10): p. 963-71.
25. Hao, Q.L., et al., Human intrathymic lineage commitment is marked by differential CD7
expression: identification of CD7- lympho-myeloid thymic progenitors. Blood, 2008. 111(3): p.
1318-26.
26. Luc, S., et al., The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential.
Nat Immunol, 2012. 13(4): p. 412-9.
27. Gruber, T, et al., Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes
That Span a T Lineage and Myeloid Continuum with Distinct Prognoses. Blood (2019) 134
(Supplement_1): 918.
28. Olsson, A., et al., Single-cell analysis of mixed-lineage states leading to a binary cell fate choice.
Nature, 2016. 537(7622): p. 698-702.
29. Bond, J., et al., A transcriptomic continuum of differentiation arrest identifies myeloid interface
acute leukemias with poor prognosis. bioRxiv, 2019: p. 2019.12.10.870121.
SCIENTIFIC
PROGRAMME
RARE SUBSETS OF
ACUTE LEUKAEMIA
TRACKING LEUKAEMIC
STEM CELLS (LSCs)
ROUTINE DIAGNOSIS
GENE EXPRESSION
AND MUTATIONAL
PROFILING
DEBATE 1 – ALL
PATIENTS WITH
INTERMEDIATE-RISK
AML MUST BE
TRANSPLANTED
INTERACTIVE
CASES 1 – MUTATION-BASED
THERAPY
OFF-LABEL
ROUNDTABLE –
SHOULD WE REALLY
USE NEW TARGETED
INHIBITORS AS SINGLE
AGENTS ?
ADDITION OF A 3RD
AGENT TO FRONTLINE
7+3
ROUNDTABLE –
CURATIVE OPTIONS
FOR OLDER AML
INTERACTIVE CASES 2
DEBATE 2 - BEST
TREATMENT FOR
NPM1-MUTATED AML IN
THE NEXT FUTURE ?
ALLOGENEIC
HAEMATOPOIETIC
STEM CELL
TRANSPLANTATION
(HSCT)
IMMUNOTHERAPY FOR
ACUTE LEUKAEMIA
DEBATE 3 - T-ALL:
WHERE ARE WE GOING
NOW?
SELECTED ABSTRACTS
AND CLINICAL
CASES FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES